1
|
Halbert M, Golbourn B, Halligan K, Varadharajan S, Krug B, Mbah N, Kabir N, Stanton AC, Locke A, Casillo S, Zhao Y, Sanders L, Cheney A, Mullett S, Chen A, Wassell M, Andren A, Perez J, Jane E, Premkumar D, Koncar R, Mirhadi S, McCarl L, Chang YF, Wu Y, Gatesman T, Cruz A, Zapotocky M, Hu B, Kohanbash G, Wang X, Vartanian A, Moran M, Lieberman F, Amankulor N, Wendell S, Vaske OM, Panigraphy A, Felker J, Bertrand KC, Kleinman C, Rich JN, Friedlander RM, Broniscer A, Lyssiotis C, Jabado N, Pollack IF, Mack SC, Agnihotri S. TMET-09. LOSS OF MAT2A COMPROMISES METHIONINE METABOLISM AND REPRESENTS A VULNERABILITY IN H3K27M MUTANT GLIOMAS. Neuro Oncol 2022. [DOI: 10.1093/neuonc/noac209.1014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Abstract
H3K27-mutant diffuse midline gliomas (DMGs) are defined as grade IV tumors by the World Health Organization. DMGs are inoperable and resistant to chemo/radio therapies. Median survival ranges from 8-11 months, with 2% of patients surviving beyond 5 years. H3K27M mutations lead to global epigenetic and transcriptional reprogramming driven by global loss of negative transcriptional regulator H3K27 trimethylation (H3K27me3). Loss of H3K27me3 is an initiating event in gliomagenesis. This disease lacks appropriate models to predict disease biology and response to treatment. Therefore, we developed a novel syngeneic H3K27M mouse model. An unbiased integrated systems biology approach identified that H3K27M but not isogenic controls relied on the amino acid methionine and the enzyme Methionine Adenosyltransferase 2A (MAT2A). MAT2A is a central regulator of one-carbon metabolism by converting methionine to S-adenosylmethionine (SAM), the universal methyl-donor for protein and nucleotide methylation reactions. In complementary genetic approaches, we applied these findings to patient-derived cell lines with the H3K27M mutation. We hypothesize that MAT2A abrogation, genetic/pharmacological, would alter DMG viability by disrupting the methylome. The current MAT2A sensitivity paradigm is based on Methylthioadenosine Phosphorylase (MTAP) deletion through a synthetic lethal mechanism. We provide a novel mechanism whereby H3K27M cells are sensitive to MAT2A loss, independent of MTAP and through Adenosylmethionine Decarboxylase 1 (AMD1) overexpression disrupting MAT2A regulation. This results in H3K27M cells having lower MAT2A protein levels, conferring a sensitivity by inhibiting residual MAT2A. Genetic/pharmacological aberrations to MAT2A resulted in reduced proliferation. Parallel H3K36me3 ChIP and RNA-sequencing identified loss of oncogenic and developmental transcriptional programs associated with MAT2A loss. In vivo syngeneic and patient-derived xenograft models with both inducible MAT2A knockdown or methionine restricted diets showed extended survival. These results suggest novel interactions between methionine metabolism and the epigenome of H3K27M gliomas and provide evidence that MAT2A, presents exploitable therapeutic vulnerabilities in histone mutant gliomas.
Collapse
Affiliation(s)
- Matthew Halbert
- University of Pittsburgh School of Medicine , Pittsburgh, PA , USA
| | | | | | | | | | - Nneka Mbah
- University of Michigan , Ann Arbor , USA
| | | | | | | | | | | | - Lauren Sanders
- University of California, Santa Cruz , Santa Cruz, CA , USA
| | | | | | - Apeng Chen
- University of Pittsburgh School of Medicine , Pittsburgh , USA
| | | | | | - Jennifer Perez
- University of Pittsburgh School of Medicine , Pittsburgh , USA
| | - Esther Jane
- University of Pittsburgh School of Medicine , Pittsburgh , USA
| | - Daniel Premkumar
- University of Pittsburgh School of Medicine , Pittsburgh, PA , USA
| | - Robert Koncar
- University of Pittsburgh School of Medicine , Pittsburgh , USA
| | | | | | | | - Yigen Wu
- University of Pittsburgh , Pittsburgh , USA
| | - Taylor Gatesman
- University of Pittsburgh School of Medicine , Pittsburgh, PA , USA
| | - Andrea Cruz
- University of Pittsburgh School of Medicine , Pittsburgh , USA
| | | | - Baoli Hu
- University of Pittsburgh School of Medicine , Pittsburgh , USA
| | - Gary Kohanbash
- University of Pittsburgh School of Medicine , Pittsburgh , USA
| | - Xiuxing Wang
- Nanjing Medical University , Nanjing , China (People's Republic)
| | | | | | | | | | - Stacy Wendell
- University of Pittsburgh School of Medicine , Pittsburgh, PA , USA
| | - Olena M Vaske
- University of California, Santa Cruz , Santa Cruz, CA , USA
| | | | | | | | | | - Jeremy N Rich
- University of Pittsburgh School of Medicine , Pittsburgh , USA
| | | | | | | | - Nada Jabado
- The Research Institute of the McGill University Health Center, Montréal, Canada
| | - Ian F Pollack
- Children's Hospital of Pittsburgh , Pittsburgh , USA
| | | | | |
Collapse
|
2
|
Nigam S, McCarl L, Kumar R, Anderson C, Edwards B, Kohanbash G. TMIC-39. DEVELOPMENT OF CD11b TRACER FOR THE IMMUNE PET IMAGING IN GLIOBLASTOMA MODEL - COULD BE A GAME CHANGER FOR IMMUNOTHERAPY APPROACHES. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz175.1073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Glioblastoma is a lethal brain tumor, heavily infiltrated by tumor-associated myeloid cells (TAMCs). As up to 30% of a glioma cellular mass may be attributed to immunosuppressive myeloid cells, including myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs). TAMCs impede natural and immunotherapy-driven anti-tumor responses, they are a high-priority and promising therapeutic target currently being evaluated in clinical trials. Multiple preclinical and clinical trials have attempted to target these cells, however monitoring of biologic responses to therapy remains a challenge. Quantifying real time status of MDSCs and TAMs at the tumor site using non-invasive immunoPET could improve therapeutic response and allow for better patient stratification and monitoring of targeted treatment responses. TAMCs highly expressed the cell surface marker, integrin CD11b (Mac-1, αMβ2) and may be a highly effective imaging target for immunoPET strategies. The human/mouse cross-reactive anti-CD11b antibody (clone M1/70) was radiolabeled with 89Zr for PET imaging. PET/CT imaging, with or without a blocking dose of anti-CD11b Ab, was performed in mice bearing established orthotopic syngeneic GL261 gliomas. Flow cytometry and histology in tissues collected from post-imaging biodistribution validated targeting of CD11b+ MDSCs and TAMs. There was significant Zr-89-anti-CD11b Ab uptake in the tumor ipsilateral right brain (SUVmean = 2.6 ± 0.24) compared to contralateral left brain (SUVmean = 0.6 ± 0.11). Blocking with 10-fold lower specific activity 89Zr-anti-CD11b Ab reduced the SUV in right brain with (SUVmean = 0.11 ± 0.06). Immune rich organs spleen and lymph nodes showed high uptake. These results correlated with biodistribution analysis. CD11b expression in the right and left brain were validated using flow cytometry, H&E and IHC, showing high CD11b expression in the right brain. Imaging TAMs and MDSCs with 89Zr-labeled anti-CD11b Ab targeting was validated in a mouse model of malignant gliomas, demonstrating the feasibility of monitoring immune response during immunotherapy.
Collapse
|
3
|
Campagna M, Ma X, McCarl L, Kumar R, Broniscer A, Agnihotri S, Felker J, Pollack I, Kohanbash G. EPEN-11. PROTEASOME AND HDAC INHIBITORS ARE CYTOTOXIC AGAINST RELA-FUSION PEDIATRIC EPENDYMOMA CELLS. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz036.068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
| | - Xiangjuan Ma
- UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA
| | - Lauren McCarl
- UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA
| | - Rajeev Kumar
- UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA
| | | | | | - James Felker
- UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA
| | - Ian Pollack
- UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA
| | - Gary Kohanbash
- UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA
| |
Collapse
|
4
|
Nigam S, McCarl L, Anderson C, Panigrahy A, Pollack I, Edwards B, Kohanbash G. IMMU-21. DEVELOPMENT OF PET TRACERS FOR NON-INVASIVE IMAGING OF IMMUNOTHERAPY IN DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz036.140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
| | - Lauren McCarl
- UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA
| | | | | | - Ian Pollack
- UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA
| | - Barry Edwards
- UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA
| | - Gary Kohanbash
- UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA
| |
Collapse
|
5
|
Koncar R, Stanton AC, Dey B, Agrawal N, Wassell M, McCarl L, Locke A, Sanders L, Vaske OM, Kohanbash G, Felker J, James CD, Hashizume R, Broniscer A, Pollack I, Agnihotri S. DIPG-11. ACTIVATION OF RAS SIGNALING AND DISTINCT MITOGEN-ACTIVATED PROTEIN KINASES (MAPKs) PROVIDES UNIQUE THERAPEUTIC VULNERABILITIES IN MUTANT HISTONE DIPG. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz036.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Robert Koncar
- John G, Rangos Sr, Research Center, Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA
- Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| | - Ann-Catherine Stanton
- John G, Rangos Sr, Research Center, Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA
- Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| | - Brittany Dey
- John G, Rangos Sr, Research Center, Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA
- Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
- SUNY Downstate Medical Center, New York, NY, USA
| | - Nishant Agrawal
- John G, Rangos Sr, Research Center, Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA
| | - Michelle Wassell
- John G, Rangos Sr, Research Center, Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA
- Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| | - Lauren McCarl
- John G, Rangos Sr, Research Center, Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA
- Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| | - Abigail Locke
- John G, Rangos Sr, Research Center, Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA
| | - Lauren Sanders
- Department of Molecular, Cell, and Developmental Biology, University of California Santa Cruz, Santa Cruz, CA, USA
| | - Olena Morozova Vaske
- Department of Molecular, Cell, and Developmental Biology, University of California Santa Cruz, Santa Cruz, CA, USA
- University of California Santa Cruz Genomics Institute, Santa Cruz, CA, USA
| | - Gary Kohanbash
- John G, Rangos Sr, Research Center, Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA
- Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| | - James Felker
- Pediatric Neuro-Oncology Program, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA
| | - C David James
- Departments of Neurological Surgery, Biochemistry and Molecular Genetics, Robert H. Lurie NCI Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Rintaro Hashizume
- Departments of Neurological Surgery, Biochemistry and Molecular Genetics, Robert H. Lurie NCI Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Alberto Broniscer
- Pediatric Neuro-Oncology Program, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA
| | - Ian Pollack
- John G, Rangos Sr, Research Center, Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA
- Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| | - Sameer Agnihotri
- John G, Rangos Sr, Research Center, Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA
- Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
- Department of Neurobiology, University of Pittsburgh, Pittsburgh, PA, USA
| |
Collapse
|
6
|
Kohanbash G, McCarl L, Shoger K, Broniscer A, Warren KE, Pollack I. IMMU-16. GUADECITABINE (SGI-110) ENHANCES MHC class I AND TUMOR ANTIGEN EXPRESSION ON MURINE C57BL/6-SYNGENEIC GLIOMA AND DIPG MODELS. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy148.519] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- Gary Kohanbash
- University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| | | | | | | | | | - Ian Pollack
- University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| |
Collapse
|